Log in to your Inderes Free account to see all free content on this page.
Respiratorius
1.30 SEK
-6.50 %
Less than 1K followers
RESP
Spotlight Stock Market
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
-6.50 %
-13.95 %
-20.06 %
-34.26 %
-65.19 %
-82.50 %
-97.18 %
-98.86 %
-90.95 %
Respiratorius is a research company focused on the development of drug candidates for the treatment of cancer, and especially aggressive lymphoma. The company was established in 1999 as a spin-off from Lund University. The operations are located in Sweden, where research is conducted in-house, but also through international partners. The company has its headquarters in Lund.
Read moreMarket cap
10.23M SEK
Turnover
48.61K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
Revenue
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
26.5.
2026
Interim report Q1'26
9.6.
2026
General meeting '26
11.8.
2026
Interim report Q2'26
All
Press releases
ShowingAll content types
Respiratorius has conducted a pre-IND meeting with the FDA
Respiratorius Granted Pre-IND Meeting with FDA for VAL001
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio